TNXP Tonix Pharmaceuticals Holdi...

Nasdaq tonixpharma.com


$ 20.16 $ -0.05 (-0.25 %)    

Tuesday, 14-Oct-2025 19:56:14 EDT
QQQ $ 598.50 $ -4.01 (-0.67 %)
DIA $ 463.08 $ 2.03 (0.44 %)
SPY $ 662.74 $ -0.81 (-0.12 %)
TLT $ 90.69 $ 0.29 (0.32 %)
GLD $ 382.95 $ 2.70 (0.71 %)
$ 20.01
$ 19.72
$ 20.00 x 100
$ 20.50 x 1
$ 19.28 - $ 20.69
$ 6.76 - $ 130.00
749,543
na
175.41M
$ 2.20
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-11-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-16-2024 06-30-2024 10-Q
6 05-13-2024 03-31-2024 10-Q
7 04-01-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-08-2023 03-31-2023 10-Q
11 03-13-2023 12-31-2022 10-K
12 11-07-2022 09-30-2022 10-Q
13 08-08-2022 06-30-2022 10-Q
14 05-09-2022 03-31-2022 10-Q
15 03-14-2022 12-31-2021 10-K
16 11-08-2021 09-30-2021 10-Q
17 08-09-2021 06-30-2021 10-Q
18 05-10-2021 03-31-2021 10-Q
19 03-15-2021 12-31-2020 10-K
20 11-09-2020 09-30-2020 10-Q
21 08-10-2020 06-30-2020 10-Q
22 05-12-2020 03-31-2020 10-Q
23 03-24-2020 12-31-2019 10-K
24 11-08-2019 09-30-2019 10-Q
25 08-12-2019 06-30-2019 10-Q
26 05-13-2019 03-31-2019 10-Q
27 03-18-2019 12-31-2018 10-K
28 11-09-2018 09-30-2018 10-Q
29 08-13-2018 06-30-2018 10-Q
30 05-11-2018 03-31-2018 10-Q
31 03-09-2018 12-31-2017 10-K
32 11-06-2017 09-30-2017 10-Q
33 08-11-2017 06-30-2017 10-Q
34 05-12-2017 03-31-2017 10-Q
35 04-13-2017 12-31-2016 10-K
36 11-10-2016 09-30-2016 10-Q
37 08-05-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 03-03-2016 12-31-2015 10-K
40 11-06-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 tonix-pharmaceuticals-ceo-highlights-tnx-1500-progress-and-anti-cd154-therapy-in-organ-transplantation-at-japan-conference

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) ("Tonix" or the "Company"), a fully integrated biotechnology ...

 tonix-pharma-plans-to-progress-tnx-2900-program-for-treatment-of-pws-into-phase-2-clinical-trial

Phase 2 randomized, double-blind, placebo-controlled trial planned to evaluate TNX-2900 in children and adolescents (ages 8 to ...

 tonix-pharmaceuticals-completes-type-b-pre-ind-meeting-with-fda-for-tnx-102-sl-for-treatment-of-major-depressive-disorder

Tonix anticipates filing the IND application in the fourth quarter of 2025TNX-102 SL is a potential first-in-class treatment fo...

 tonix-pharmaceuticals-announces-in-licensing-of-tnx-4800-monoclonal-antibody-for-annual-lyme-disease-prevention-across-us-endemic-regions

Positive Phase 1 study showed safety, tolerability and a linear pharmacokinetic: pharmacodynamic: efficacy relationship (1: 1: ...

 tonix-presents-clinical-data-on-tonmya-for-treatment-of-fibromyalgia-at-painweek-conference-2025-phase-3-data-support-q4-launch-following-painweek-showcase

Tonmya was approved by FDA on August 15, 2025 for the treatment of fibromyalgia and is the first new FDA approved treatment for...

 tonix-pharmas-drug-gets-fda-nod-for-chronic-pain-condition-first-new-therapy-in-over-15-years

FDA approves Tonmya, a non-opioid fibromyalgia therapy from Tonix, with strong trial data and U.S. launch expected in late 2025.

 fda-approves-tonix-pharmas-tonmya-for-treatment-of-fibromyalgia-in-adults

Tonmya is the first FDA-approved therapy for the treatment of fibromyalgia in over 15 yearsFibromyalgia is a chronic pain condi...

 whats-going-on-with-tonix-pharmaceuticals-tnxp-stock

Shares of Tonix Pharmaceuticals have rallied 30% over the past five sessions. Investors are anticipating a key catalyst for the...

 why-tonix-pharmaceuticals-tnxp-stock-is-climbing-this-week

Shares of Tonix Pharmaceuticals are building on recent gains. The stock is trading higher as investor focus intensifies on a ke...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION